Jingjing Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jingjing Liu has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Jianhua Zhang
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
38 shared publications - Xingzhi Song
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
38 shared publications - Amado Zurita-Saavedra
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
29 shared publications - Ana M. Aparicio
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
29 shared publications - Andrew W. Hahn
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
29 shared publications - Chad D. Huff
University of Texas MD Anderson Cancer Center
29 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
Peripheral blood lymphocyte, monocyte, and platelet dynamics following sotigalimab and pembrolizumab combination treatment
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
Peripheral blood lymphocyte, monocyte, and platelet dynamics following sotigalimab and pembrolizumab combination treatment
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
The combination of sotigalimab and pembrolizumab induces broad innate and adaptive immune activation in injected and non-injected tumors
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
The combination of sotigalimab and pembrolizumab induces broad innate and adaptive immune activation in injected and non-injected tumors
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
Immunological changes in injected tumors induced by sotigalimab in combination with pembrolizumab, compared to anti-PD-1 monotherapy.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
Immunological changes in injected tumors induced by sotigalimab in combination with pembrolizumab, compared to anti-PD-1 monotherapy.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 12 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
Clinical responses to the combination of sotigalimab and pembrolizumab do not require MHC class II expression or IFN-g–mediated immune activation at baseline
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 12 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
Clinical responses to the combination of sotigalimab and pembrolizumab do not require MHC class II expression or IFN-g–mediated immune activation at baseline
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 13 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
The impact of intratumoral CD40 agonist in combination with PD1 therapy on tumor immune landscape at single cell resolution in an immune-cold melanoma model
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 13 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
The impact of intratumoral CD40 agonist in combination with PD1 therapy on tumor immune landscape at single cell resolution in an immune-cold melanoma model
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 14 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
Changes in intratumoral immune cell populations in response to different therapies identified through scRNA-seq analysis
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 14 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
Changes in intratumoral immune cell populations in response to different therapies identified through scRNA-seq analysis
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
Sotigalimab effectively engages the CD40 pathway and induced the rapid infiltration and activation of APCs in injected tumors
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
Sotigalimab effectively engages the CD40 pathway and induced the rapid infiltration and activation of APCs in injected tumors
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
Baseline biomarkers and clinical responses: ORR by PD-L1, LDH, and BRAF Status, and baseline LDH/tumor burden in all treated patients.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
Baseline biomarkers and clinical responses: ORR by PD-L1, LDH, and BRAF Status, and baseline LDH/tumor burden in all treated patients.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
Clinical responses to sotigalimab and pembrolizumab in all treated patients (n = 32) and in patients treated at the RP2D (n = 24)
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
Clinical responses to sotigalimab and pembrolizumab in all treated patients (n = 32) and in patients treated at the RP2D (n = 24)
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
Objective responses by baseline PD-L1, LDH, and BRAF status in patients treated with sotigalimab plus pembrolizumab in all treated patients (n = 32)
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
Objective responses by baseline PD-L1, LDH, and BRAF status in patients treated with sotigalimab plus pembrolizumab in all treated patients (n = 32)